MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
Go back to MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates| (NASDAQ: INKT) | Delayed: 11.45 -0.19 (1.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.64 | 52 Week High | $ | |||
| Open | $11.61 | 52 Week Low | $ | |||
| Day High | $11.85 | P/E | N/A | |||
| Day Low | $11.45 | EPS | $ | |||
| Volume | 11,019 | |||||

